Evidence map›Paper›PMID 36741980›Full record

ArticleFrontiers in cellular and infection microbiology2022

Characterization of serum biomarkers and antibody responses against

Lena Amend, Benoît Thomas P Gilbert, Penelope Pelczar, Marius Böttcher, Samuel Huber, Torsten Witte, Axel Finckh, Till Strowig

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Lena AmendDepartment of Microbial Immune Regulation, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Benoît Thomas P GilbertDivision of Rheumatology, Geneva University Hospitals, Geneva, Switzerland.
Penelope PelczarI. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Marius BöttcherI. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Samuel HuberI. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Torsten WitteDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Axel FinckhDivision of Rheumatology, Geneva University Hospitals, Geneva, Switzerland.
Till StrowigDepartment of Microbial Immune Regulation, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Helmholtz Centre for Infection Research · DEUniversität Hamburg · DEUniversity Hospital of Geneva · CHMedizinische Hochschule Hannover · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The characterization of the influence of the microbiota on the development and drug responses during rheumatic diseases has intensified in recent years. The role of specific bacteria during disease development has become a central research question. Notably, several lines of evidence point to distinct microbes, e.g., Methods: In the present study, we compiled a broad collection of human serum samples from individuals at risk of developing RA, chronic RA patients as well as patients with new-onset of rheumatic diseases. We evaluated the presence of inflammatory biomarkers in our serum collection as well as serum antibody responses against novel, genetically distinct isolates of Results: Our analysis revealed the presence of increased levels of inflammatory markers already in pre-clinical and new onset rheumatoid arthritis. However, antibody reactivity against the microbes did not differ between patient groups. Yet, we observed high variability between the different Discussion: In conclusion, our work underlined the importance of strain-level characterization and its consideration during further investigations of host-microbiota interactions and the development of microbiome-based therapeutic approaches for treating rheumatic diseases.

Indexed as

Antibody FormationRheumatic DiseasesBiomarkersHumansImmunoglobulin GPrevotellaBiomarkersImmunoglobulin Gbiomarkersgut microbiotapreclinical disease stagesPrevotella coprirheumatoid arthritisspondyloarthritis

Identifiers

PMID36741980
PMCPMC9889664
OpenAlexW4317037001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.